Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 5;24(2):1045.
doi: 10.3390/ijms24021045.

Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?

Massimo Martino  1   2 , Filippo Antonio Canale  1   2 , Virginia Naso  1   2 , Gaetana Porto  1   2 , Demetrio Gerace  3 , Alessandro Allegra  3
Affiliations
Review

Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?

Massimo Martino et al. Int J Mol Sci. .

Abstract

Allogeneic stem cell transplantation (allo-SCT) represented the first immunotherapy to treat hematologic malignancies: it has been considered as a cure for the disease and never as an approach to extend the life of patients. The success of allo-SCT derives both from the ability to treat patients with intensive chemoradiotherapy and from the potent graft-versus-leukemia effects mediated by donor immunity. Although considerable progress has been made in the last years, significant barriers still remain in the form of disease relapse, graft-versus-host disease, infectious complications, and regimen-related toxicities. Moreover, the treatment of hematologic malignancies, particularly acute lymphoblastic leukemia and certain forms of lymphomas, has been revolutionized by the commercial introduction of genetically modified autologous T-lymphocyte therapy (CAR-T). Our review discusses current standards and the shifting paradigms in the indications for allo-SCT and the role of CAR-T cell therapy for lymphoid neoplasms.

Keywords: CAR-T treatment; acute lymphoblastic leukemia; allogeneic stem cell transplantation; autologous stem cell transplantation; diffuse large B cell lymphoma; lymphoproliferative diseases; mantle cell lymphoma; relapsed lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
CD19 and BCMA-directed CAR T-cells comprising a CD19 or a BCMA antigen-binding domain, a costimulatory domain (generally CD28 or 4-1BB), and a CD3-ζsignaling domain.
Figure 2
Figure 2
Fitting CAR-T Cell Therapy Into Current Treatment Paradigms in DLBCL.
Figure 3
Figure 3
Fitting CAR T-Cell Therapy Into Current Treatment Paradigms in MCL.
Figure 4
Figure 4
Fitting CAR T-Cell Therapy Into Current Treatment Paradigms in ALL.
See this image and copyright information in PMC

References

    1. Singh A.K., McGuirk J.P. Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview. Cancer Res. 2016;76:6445–6451. doi: 10.1158/0008-5472.CAN-16-1311. - DOI - PubMed
    1. Petersen S.L. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Dan. Med. Bull. 2007;54:112–139. - PubMed
    1. Timofeeva O.A., Philogene M.C., Zhang Q.J. Current donor selection strategies for allogeneic hematopoietic cell transplantation. Hum. Immunol. 2022;83:674–686. doi: 10.1016/j.humimm.2022.08.007. - DOI - PubMed
    1. Mushtaq M.U., Shhzad M., Tariq E., Iqbal Q., Chaudhary S.G., Zafar M.U., Anwar I., Ahmed N., Bansal R., Singh A.K., et al. Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis. Front. Oncol. 2022;12:1005042. doi: 10.3389/fonc.2022.1005042. - DOI - PMC - PubMed
    1. Passweg J.R., Baldomero H., Chabannon C., Corbacioglu S., de la Cámara R., Dolstra H., Glass B., Greco R., Mohty M., Neven B., et al. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: A report from the EBMT activity survey. Bone Marrow Transplant. 2022;57:742–752. doi: 10.1038/s41409-022-01604-x. - DOI - PMC - PubMed

MeSH terms

Substances